Abnormal elevation of serum potassium levels (greater than or equal to 5.5 mEq/liter) can occur with all potassium-sparing agents, including Dyrenium. Hyperkalemia is more likely to occur in patients with renal impairment and diabetes (even without evidence of renal impairment), and in the elderly or severely ill. Since uncorrected hyperkalemia may be fatal, serum potassium levels must be monitored at frequent intervals especially in patients receiving Dyrenium, when dosages are changed or with any illness that may influence renal function.
Each capsule for oral use, with opaque red cap and body, contains Triamterene USP, 50 or 100 mg, and is imprinted with the product name, DYRENIUM, strength (50 mg or 100 mg) and WPC 002 (for the 50-mg strength) and WPC 003 (for the 100-mg strength).
Dyrenium (triamterene) is indicated in the treatment of edema associated with congestive heart failure, cirrhosis of the liver and the nephrotic syndrome; steroid-induced edema, idiopathic edema and edema due to secondary hyperaldosteronism.
Dyrenium may be used alone or with other diuretics, either for its added diuretic effect or its potassium-sparing potential. It also promotes increased diuresis when patients prove resistant or only partially responsive to thiazides or other diuretics because of secondary hyperaldosteronism.
. The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia.
Usage in Pregnancy
Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy (however, see below) when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate.
Published Studies Related to Dyrenium (Triamterene)
Bioequivalence evaluation of a triamterene-hydrochlorothiazide generic product: a new bioequivalence index for fixed-dose combinations. [2011.02]
In this study, an open, double-blind, randomized, two-period, two-group crossover design was conducted in 14 healthy volunteers to study the bioequivalence of a fixed-dose generic product. After administration of test or reference products to each volunteer, both active ingredients were determined simultaneously in plasma samples using a developed and validated HPLC-UV method, and pharmacokinetic parameters, including C(max), T(max), AUC(0-t) , AUC(0infinity), terminal elimination rate constant (lambdaz), volume of distribution in steady state (Vd(ss)), mean residence time (MRT), clearance (Cl), terminal elimination rate constant (Kel) were determined in each subject using the standard non-compartmental approach...
Attenuation of the kaluretic properties of furosemide by triamterene (Dyrenium) in healthy volunteers. [2005.02]
OBJECTIVE: To examine if concomitant administration of furosemide, a loop diuretic, with the potassium- and magnesium-sparing diuretic triamterene would decrease loss of potassium and magnesium while improving diuresis... CONCLUSION: Triamterene, when used in combination with the loop diuretic, furosemide, preserves intracellular potassium and magnesium while enhancing the natriuretic effect of furosemide.
Effect of quinapril and triamterene/hydrochlorothiazide on cardiac and vascular end-organ damage in isolated systolic hypertension. [1998.02]
We compared, in a prospective double-blind randomized study, the effect of the angiotensin-converting enzyme inhibitor quinapril (QUI) with that of triamterene/hydrochlorothiazide (THCT) treatment on cardiovascular end-organ damage in subjects with untreated isolated systolic hypertension (ISH)... Results of LV diastolic function and peripheral vascular resistance were less clear but appear to show less favorable changes in the THCT subjects treatment group.
Pharmacokinetics and pharmacodynamics of triamterene and hydrochlorothiazide and their combination in healthy volunteers. [1997.10]
Although triamterene has been in clinical use for over 30 years, the linearity of triamterene kinetics was not systematically tested. Moreover, although triamterene is mostly applied concomitantly with thiazide-type diuretics the interaction of triamterene (TA) with hydrochlorothiazide (HCT) is subject to a controversial discussion.
Felodipine or hydrochlorothiazide/triamterene for treatment of hypertension in the elderly: effects on blood pressure, hypertensive heart disease, metabolic and hormonal parameters. [1996.05]
The aim of the study was to compare the antihypertensive efficacy of either felodipine or the diuretic combination hydrochlorothiazide/triamterene in a group (n = 65) of elderly (> or = 70 years) hypertensives (office blood pressure > or = 160/95 mmHg) with special regard to ambulatory blood pressure monitoring, hypertensive heart disease and metabolic parameters...
Clinical Trials Related to Dyrenium (Triamterene)
A Crossover Pilot Study of the Effect of Amiloride on Proteinuria [Recruiting]
This cross-over study is designed to test the hypothesis that amiloride will reduce urinary
protein excretion and protect the kidney from rapid progression in proteinuric kidney
Diuretics, Hypertension, and Arrhythmias Clinical Trial [Completed]
To determine whether hypertensive patients with ECG abnormalities and receiving
hydrochlorothiazide diuretics were at increased risk of sudden death.
Increased Activity of a Renal Salt Transporter (ENaC) in Diabetic Kidney Disease [Enrolling by invitation]
The purpose of the study is to determine whether a diuretic drug called amiloride is capable
of increasing renal salt excretion and thereby decrease blood pressure in diabetic patients
with kidney disease. Our hypothesis states that amiloride is capable of reducing blood
pressure in these patients and thus decrease the cardiovascular risk associated with
diabetic kidney disease.
Action to Control Cardiovascular Risk in Diabetes (ACCORD) [Completed]
The purpose of this study is to prevent major cardiovascular events (heart attack, stroke,
or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic
control, intensive blood pressure control, and multiple lipid management.
Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension [Completed]
Plasma renin values determine whether volume or vasoconstrictor (renin) factors predominate
in elevating blood pressure and are useful in selecting effective antihypertensive
The researchers hypothesize that:
1. Plasma renin-guided therapeutics will improve systolic and diastolic blood pressure
control in patients with untreated hypertension as well as in patients with treatment
refractory or resistant hypertension that are managed by Clinical Hypertension
2. Renin-guided therapeutics will reduce the number of medications required to maintain
blood pressure control to <140/90 mmHg in hypertensive patients receiving 3 or more
medications, while under the care of a Clinical Hypertension Specialist.
3. Renin-guided therapeutics selection will reduce the total cost of antihypertensive care
provided by Clinical Hypertension Specialists.
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 2 ratings/reviews, Dyrenium has an overall score of 9.50. The effectiveness score is 8 and the side effect score is 7. The scores are on ten point scale: 10 - best, 1 - worst.
Dyrenium review by 59 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Considerably Effective|
|Side effects:|| || Moderate Side Effects|
|Condition / reason:|| || hypertension|
|Dosage & duration:|| || .37 mg taken daily for the period of years|
|Other conditions:|| || low potassium|
|Other drugs taken:|| || potassium supplements|
|Benefits:|| || Normal blood pressure|
|Side effects:|| || Depletion of potassium, and heat and cold sensitivity (inability for body to regulate temp)|
|Comments:|| || I was diagnosed with mild hypertension at age 24. I began taking HTCZ at that age and am still on them. I also began taking Cozaar about 4 years ago as the HTCZ wasn't quite enough.|
Dyrenium review by 28 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Considerably Effective|
|Side effects:|| || Mild Side Effects|
|Condition / reason:|| || high blood pressure|
|Dosage & duration:|| || 150 mg taken once daily for the period of two years|
|Other conditions:|| || none|
|Other drugs taken:|| || none|
|Benefits:|| || Reduced swelling due to water retention; reduced high blood pressure.|
|Side effects:|| || Dry mouth and night sweats.|
|Comments:|| || One dose daily was immediately effective in reducing swelling; blood pressure was reduced within 3 weeks. Night sweats and dry mouth were the primary side effects. Moderate weight loss (water weight) occurred within one week (total five pounds).|
Page last updated: 2011-12-09